A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies

Clinical Immunology

Volumn 111, Issue 3, 2004, Pages 303-310

  Letko, Erik ^a   Miserocchi, Elisabetta ^a   Daoud, Yassine J ^a   Christen, William ^b   Foster, C Stephen ^a   Ahmed, A Razzaque ^a,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Cicatricial pemphigoid; Immunosuppressive therapy; Intravenous immunoglobulin therapy; Mucous membrane pemphigoid; Ocular cicatricial pemphigoid

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ECCHYMOSIS; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; LEUKOPENIA; MALE; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; OSTEOPOROSIS; PHYSICIAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SCAR FORMATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; CONJUNCTIVAL DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; TREATMENT OUTCOME;

EID: 2942620605     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.11.002     Document Type: Article

References (20)

1. Ahmed A.R., Kurgis B.S., Rogers R.S., et al. Cicatricial pemphigoid. J. Am. Acad. Dermatol. 24:1991;987-1000
2. Neumann R., Tauber J., Foster C.S. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 98:1991;858-862
3. Mondino B.J. Cicatricial pemphigoid and erythema multiforme. Ophthalmology. 97:1990;939-952
4. Dave V.K., Vickers C.F.H. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br. J. Dermatol. 90:1974;183-186
5. Brody H.I., Pirozzi D.J. Benign mucous membrane pemphigoid: response to therapy with cyclophosphamide. Arch. Dermatol. 113:1977;1598-1599
6. Foster C.S. Cicatricial pemphigoid. Trans. Am. Ophthalmol. Soc. 84:1986;527-663
7. Mondino B.J., Brown S.I. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am. J. Ophthalmol. 96:1983;453-459
8. Foster C.S., Neumann R., Tauber J. Long term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc. Ophthalmol. 82:1992;223-229
9. Foster C.S., Wilson L.A., Ekins M.B. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 89:1982;340-353
10. Foster C.S., Ahmed R.A. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. A preliminary study. Ophthalmology. 106:1999;2136-2143
11. Chan R.Y., Bhol K., Tesavibul N., et al. The role of antibody to human β4-integrin in conjunctival basement membrane separation, possible in vitro model for ocular cicatricial pemphigoid. Invest. Ophthalmol. Visual Sci. 40:1999;2283-2290
12. Lee S.J., Li Z., Sherman B., Foster C.S. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest. Ophthalmol. Visual Sci. 34:1993;3522-3525
13. Okitsu Negishi S., Furusawa S., Kawa Y., et al. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol. Res. 13:1994;49-55
14. Menezes M.C., Benard G., Sato M.N., et al. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int. Arch. Allergy Immunol. 114:1997;323-328
15. Ruiz De Souza V., Carreno M.P., Kaveri S.V., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur. J. Immunol. 25:1995;1267-1273
16. Ling Z.D., Yeoh E., Webb B.T., et al. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J. Clin. Immunol. 13:1993;302-309
17. Fehr J., Hoffman V., Kapeller U. Transient reversal of thrombocytopenic purpura by high dose intravenous gammaglobulin. N. Engl. J. Med. 306:1982;1254-1258
18. Frank M.M., Basta M., Fries L.F. The effects of intravenous immunoglobulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 62:1992;S82-S86
19. Dietrich G., Kazatchkine M.D. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specifities against an immunodominant, disease associated, cross reactive idiotype of human anti-thyroglobulin autoantibodies. J. Clin. Invest. 85:1990;620-625
20. Letko E., Bhol K., Foster C.S., Ahmed A.R. Influence of intravenous immunoglobulin on serum levels of anti-beta4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr. Eye Res. 21:2000;646-654